# US 2024/0197718 A1 · Therapeutic or prophylactic agent for cachexia accompanied by ghrelin resistance

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197718 A1
- Document ID: US20240197718A1
- Status: Published application
- Kind: A1
- Application number: 18/286,379
- Filed: 2022-04-22
- Published: 2024-06-20
- Earliest claimed: 2021-04-23
- Assignees: Toray Industries, Inc.
- Applicants: Toray Industries, Inc.
- Inventors: Masashi Uchida; Yu Omori
- Web page: https://patentgrep.com/patent/US20240197718A1

## CPC

- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

There is a problem of providing a therapeutic or prophylactic agent for cachexia accompanied by ghrelin resistance. The therapeutic or prophylactic agent for cachexia accompanied by ghrelin resistance contains, as an active ingredient, an opioid κ receptor agonist compound represented by the formula (I):

## Claims

### Claim at position 1

1-6. (canceled)

### Claim 7

A method of treating or preventing cachexia accompanied by ghrelin resistance, the method comprising a step of administering an opioid κ receptor agonistic compound.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the opioid κ receptor agonistic compound is a compound represented by General Formula (I) or a pharmacologically acceptable acid addition salt thereof:
wherein a double line composed of a dotted line and a solid line represents a double bond or a single bond, R1 represents a cycloalkylalkyl having 4 to 7 carbon atoms, R2 represents a linear or branched alkyl having 1 to 5 carbon atoms, and B represents a —CH═CH—.

### Claim 9 (depends on 8)

The method according to claim 8, wherein R1 is a cyclopropylmethyl, a cyclobutylmethyl, a cyclopentylmethyl, or a cyclohexylmethyl, and R2 is a methyl, an ethyl, or a propyl.

### Claim 10 (depends on 8)

The method according to claim 8, wherein R1 is a cyclopropylmethyl, R2 is a methyl, and B is a trans-form —CH═CH—.

### Claim 11 (depends on 8)

The method according to claim 8, wherein the compound represented by General Formula (I) is (−)-17-(cyclopropylmethyl)-3,14β-dihydroxy-4,5α-epoxy-6β-[N-methyl-trans-3-(3-furyl)acrylamide]morphinan represented by:

### Claim 12 (depends on 7)

The method according to claim 7, wherein the cachexia is cancer cachexia.